
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>eMANDEVAL-Future – Technical appendix</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <style>
    :root {
      --bg-page: #f4f5fb;
      --bg-card: #ffffff;
      --border-subtle: #d2d6dc;
      --border-strong: #b6bed9;
      --text-main: #111827;
      --text-muted: #6b7280;
      --primary: #325dff;
      --primary-deep: #2237c9;
      --chip-good: #16a34a;
      --chip-med: #ea580c;
      --chip-bad: #b91c1c;
    }

    * {
      box-sizing: border-box;
    }

    body {
      margin: 0;
      padding: 0;
      font-family: system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
      color: var(--text-main);
      background: radial-gradient(circle at top left, #eef2ff, #f4f5fb 52%, #edf2ff 100%);
    }

    .page {
      max-width: 950px;
      margin: 22px auto 26px auto;
      padding: 0 16px 22px 16px;
    }

    header {
      padding: 10px 0 6px 0;
      border-bottom: 3px solid var(--primary);
      margin-bottom: 16px;
    }

    header h1 {
      margin: 0;
      font-size: 1.5rem;
      letter-spacing: 0.01em;
    }

    header p {
      margin: 3px 0 0 0;
      font-size: 0.9rem;
      color: var(--text-muted);
    }

    header .small {
      margin-top: 4px;
    }

    h2 {
      margin-top: 16px;
      margin-bottom: 6px;
      font-size: 1.1rem;
    }

    h3 {
      margin-top: 12px;
      margin-bottom: 4px;
      font-size: 0.98rem;
    }

    h4 {
      margin-top: 10px;
      margin-bottom: 2px;
      font-size: 0.9rem;
    }

    p {
      margin: 4px 0;
      font-size: 0.9rem;
    }

    ul {
      margin: 4px 0 6px 18px;
      font-size: 0.9rem;
    }

    .card {
      background: var(--bg-card);
      border-radius: 10px;
      padding: 12px 14px;
      border: 1px solid var(--border-subtle);
      margin-bottom: 12px;
      box-shadow: 0 10px 24px rgba(15, 23, 42, 0.04);
    }

    .pill {
      display: inline-block;
      padding: 2px 8px;
      border-radius: 999px;
      background: #e5edff;
      color: #0b3d91;
      font-size: 0.7rem;
      font-weight: 600;
      text-transform: uppercase;
      letter-spacing: 0.04em;
      margin-bottom: 2px;
    }

    .pill.secondary {
      background: #eef2ff;
      color: #1d4ed8;
    }

    .grid-2 {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(260px, 1fr));
      gap: 10px;
    }

    .highlight {
      background: #ecf5ff;
      border-left: 3px solid #1557bf;
      padding: 6px 8px;
      font-size: 0.9rem;
      border-radius: 4px;
    }

    .note {
      background: #fffbeb;
      border-left: 3px solid #d97706;
      padding: 5px 8px;
      font-size: 0.86rem;
      border-radius: 4px;
      margin-top: 4px;
    }

    table {
      width: 100%;
      border-collapse: collapse;
      font-size: 0.82rem;
      margin-top: 4px;
    }

    table th,
    table td {
      border: 1px solid #e5e7eb;
      padding: 3px 4px;
      text-align: left;
    }

    table thead {
      background: #f3f4f6;
    }

    .small {
      font-size: 0.8rem;
      color: var(--text-muted);
    }

    .tag {
      display: inline-block;
      font-size: 0.72rem;
      padding: 1px 6px;
      border-radius: 6px;
      background: #e5e7eb;
      margin-right: 4px;
      margin-bottom: 2px;
    }

    .chip-row {
      margin-top: 4px;
      display: flex;
      flex-wrap: wrap;
      gap: 4px;
    }

    .chip {
      display: inline-flex;
      align-items: center;
      padding: 2px 8px;
      font-size: 0.74rem;
      border-radius: 999px;
      border: 1px solid rgba(148, 163, 184, 0.7);
      background: #f9fafb;
    }

    .chip.good {
      border-color: rgba(34, 197, 94, 0.4);
      color: var(--chip-good);
      background: #dcfce7;
    }

    .chip.med {
      border-color: rgba(234, 88, 12, 0.4);
      color: var(--chip-med);
      background: #ffedd5;
    }

    .chip.bad {
      border-color: rgba(185, 28, 28, 0.4);
      color: var(--chip-bad);
      background: #fee2e2;
    }

    .changelog {
      font-size: 0.82rem;
    }

    .inline-math {
      font-family: "SF Mono", ui-monospace, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace;
      font-size: 0.82rem;
    }

    .subtle-box {
      background: #f3f4ff;
      border-radius: 6px;
      padding: 6px 8px;
      border: 1px solid #c7d2fe;
      font-size: 0.86rem;
    }

    @media print {
      body {
        background: #ffffff;
      }
      .card {
        box-shadow: none;
      }
    }
  </style>
</head>
<body>
  <div class="page">
    <header>
      <h1>eMANDEVAL-Future – Technical appendix</h1>
      <p>Methods, parameters and guidance for the online decision aid on potential future COVID-19 vaccine mandates (Australia, France, Italy).</p>
      <p class="small">Version v2.0.0 &nbsp;|&nbsp; Build date: Jan 2026</p>
    </header>

    <section class="card">
      <span class="pill">Overview</span>
      <h2>1. Purpose and scope</h2>
      <p>
        This appendix documents the main inputs, modelling assumptions and outputs used in eMANDEVAL-Future, an online
        decision aid for exploring the consequences of different COVID-19 vaccine mandate designs in Australia, France
        and Italy.
      </p>
      <p>
        eMANDEVAL-Future combines preference estimates from a discrete choice experiment (DCE) with simple epidemiological
        and costing inputs to provide:
      </p>
      <ul>
        <li>Model-based predicted public support for a given mandate configuration.</li>
        <li>Expected lives saved in the exposed population, based on a “lives saved per 100,000” input.</li>
        <li>Monetary valuation of lives saved using a configurable benefit metric (for example, a value of statistical life).</li>
        <li>Implementation costs, net benefit and benefit–cost ratios (BCRs).</li>
        <li>“Lives-saved equivalents” (marginal rate of substitution, MRS) to interpret preferences over mandate design features.</li>
        <li>Storage, comparison and export of multiple scenarios, including AI-ready policy briefing prompts.</li>
      </ul>
      <p class="note">
        The tool is designed as a transparent decision aid for exploring potential future mandates, not as a forecasting
        engine. Legal, ethical, equity and political considerations must be assessed separately.
      </p>
    </section>

    <section class="card">
      <span class="pill">Workflow</span>
      <h2>2. How the workflow and tabs fit together</h2>
      <div class="grid-2">
        <div>
          <h3>2.1. Question-first workflow (policy modes)</h3>
          <p>
            The tool can be used in a configuration-first way or in a guided “policy question” mode. On the main screen,
            users can indicate what they are mainly trying to do, for example:
          </p>
          <ul>
            <li>Compare a strict versus lenient mandate.</li>
            <li>Maximise support subject to BCR&nbsp;≥&nbsp;1.</li>
            <li>Maximise BCR subject to support&nbsp;≥&nbsp;X%.</li>
            <li>Compare country A versus B for similar mandate designs.</li>
          </ul>
          <p>
            These choices do not change the underlying model, but they highlight which inputs to focus on and suggest
            useful scenario templates (for example “minimal mandate” versus “strict mandate”) to support a question-first
            workflow.
          </p>

          <h3>2.2. Settings</h3>
          <p>
            The <strong>Settings</strong> tab defines the population, analysis horizon and benefit metric. These apply to
            all scenarios:
          </p>
          <ul>
            <li><strong>Analysis horizon:</strong> number of years during which costs and benefits are considered.</li>
            <li><strong>Population covered:</strong> number of people exposed to the mandate.</li>
            <li>
              <strong>Benefit metric and value per life saved / equivalent:</strong> a monetary value aligned, where
              possible, with national regulatory guidance or health-sector thresholds (for example a value of statistical
              life, a value per QALY, or health system savings per avoided death).
            </li>
          </ul>
        </div>

        <div>
          <h3>2.3. Mandate configuration</h3>
          <p>
            The <strong>Configuration</strong> tab selects the country, outbreak scenario and mandate design. The mixed
            logit model then calculates the model-based probability that people would support this mandate over an opt-out
            (no mandate) option:
          </p>
          <ul>
            <li>Country (Australia, France, Italy).</li>
            <li>Outbreak scenario (mild / endemic versus severe outbreak).</li>
            <li>Scope (high-risk occupations only vs all occupations and public spaces).</li>
            <li>Exemption policy (medical only; medical + religious; medical + religious + personal belief).</li>
            <li>Coverage threshold to lift the mandate (50%, 70% or 90% vaccinated).</li>
            <li>Expected lives saved per 100,000 people (for example 10, 25, 35 or 40).</li>
          </ul>

          <h3>2.4. Costing</h3>
          <p>
            The <strong>Costing</strong> tab allows users to enter indicative implementation costs across standard
            categories (digital systems, communications, enforcement, compensation, administration, other costs). The tool
            also offers country- and outbreak-specific default cost suggestions per million population, which can be
            loaded and edited.
          </p>
        </div>
      </div>

      <h3>2.5. Results and interpretation</h3>
      <p>
        The <strong>Results</strong> tab combines preference-based support, epidemiological inputs and costs to produce:
      </p>
      <ul>
        <li>Total lives saved in the exposed population.</li>
        <li>Monetary value of lives saved based on the selected benefit metric.</li>
        <li>Total implementation cost, net benefit and benefit–cost ratio.</li>
        <li>
          Lives-saved equivalents (MRS) that translate changes in mandate features into “equivalent lives saved per
          100,000 people”.
        </li>
        <li>Simple visual summaries (cost–benefit bar chart, support vs opt-out, and MRS bars).</li>
      </ul>
      <p>
        Status chips flag whether predicted support and the benefit–cost ratio appear broadly high, medium or low, based
        on transparent numerical thresholds (for example support &lt;50%, 50–70%, ≥70%; BCR &lt;0.8, 0.8–1.0, ≥1.0). These
        are descriptive labels, not decision rules.
      </p>

      <h3>2.6. Saved scenarios, comparison dashboard and briefings</h3>
      <p>
        The <strong>Saved scenarios</strong> tab stores complete scenarios (settings, configuration, costs and results)
        for comparison and export. Version 2.0 adds:
      </p>
      <ul>
        <li>
          A compact comparison dashboard where up to three scenarios can be “pinned” and compared side-by-side using a
          small radar chart (support, BCR, total lives saved, total cost) and simple traffic-light stripes.
        </li>
        <li>
          Scenario-to-scenario numerical deltas (for example “Scenario B gains +12 percentage points in support and +0.3
          in BCR compared with Scenario A”).
        </li>
        <li>
          One-click exports to CSV / Excel-readable files and to a Word briefing document with structured scenario
          summaries.
        </li>
      </ul>
      <p>
        The <strong>Briefings &amp; AI prompts</strong> tab helps users translate scenarios into short policy briefings or
        detailed prompts for Copilot / ChatGPT. When multiple scenarios are saved, the AI prompt focuses on comparative
        analysis across options.
      </p>
      <div class="note">
        A presentation mode is available to support meetings and workshops. It switches to a dark, high-contrast view
        while preserving all calculations.
      </div>
    </section>

    <section class="card">
      <span class="pill">Interpretation</span>
      <h2>3. Predicted public support</h2>
      <p>
        eMANDEVAL-Future reports “predicted public support” as the model-based probability that a respondent would choose
        a given mandate over an opt-out option, conditional on the country and outbreak frame.
      </p>
      <p>
        The underlying utility functions are:
      </p>
      <ul>
        <li><strong>U(mandate):</strong> utility from a mandate with specific scope, exemptions, coverage and lives saved.</li>
        <li><strong>U(opt-out):</strong> utility from the “no mandate” option.</li>
      </ul>
      <p class="highlight">
        For a given vector of random preferences β, the model-based probability of choosing the mandate is:
        <br />
        <span class="inline-math">P(mandate | β) = exp(U(mandate; β)) / [exp(U(mandate; β)) + exp(U(opt-out; β))]</span>.
      </p>
      <p>
        Preferences β are assumed to follow a multivariate normal distribution, estimated separately for each country and
        outbreak frame. In the application, this is implemented by simulating 1,000 independent draws for each random
        coefficient using a fixed pseudo-random seed to ensure reproducibility. For each draw, the tool computes
        <span class="inline-math">P(mandate | β<sub>r</sub>)</span> and then averages over draws:
      </p>
      <p class="inline-math">
        Predicted support = (1 / R) · Σ<sub>r=1,…,R</sub> P(mandate | β<sub>r</sub>), with R = 1,000.
      </p>
      <p class="small">
        Interpretation: a predicted support of 65% means that, under the stated conditions and extrapolating from the DCE,
        around two thirds of respondents would choose the mandate over no mandate. It is not a forecast of compliance or
        turnout and should be interpreted as an indicative acceptability measure.
      </p>
    </section>

    <section class="card">
      <span class="pill">Methods</span>
      <h2>4. Discrete choice experiment and mixed logit models</h2>

      <h3>4.1. Attributes and levels</h3>
      <p>
        The DCE asked respondents to choose between two mandate options and an opt-out alternative. Mandates were
        described using:
      </p>
      <ul>
        <li>Scope (high-risk occupations only vs all occupations &amp; public spaces).</li>
        <li>Exemption policy (medical only; medical + religious; medical + religious + personal belief).</li>
        <li>Coverage threshold to lift the mandate (50%, 70% or 90% of the population vaccinated).</li>
        <li>Expected lives saved per 100,000 people (for example 10, 25, 35 or 40).</li>
      </ul>

      <h3>4.2. Mixed logit specification</h3>
      <p>
        For each country (Australia, France, Italy) and outbreak frame (mild / endemic, severe), a mixed logit (random
        parameters logit) model was estimated with normally distributed random coefficients:
      </p>
      <ul>
        <li>Alternative-specific constant (ASC) for the Policy A mandate alternative.</li>
        <li>ASC for the opt-out (no mandate) alternative.</li>
        <li>Dummy variables for scope, exemptions and coverage threshold levels.</li>
        <li>A continuous coefficient for expected lives saved per 100,000 people.</li>
      </ul>

      <p>
        The tool uses the estimated means and standard deviations of these random coefficients to generate 1,000 draws
        from independent normal distributions. For each draw, utilities for the mandate and opt-out options are computed
        at the chosen configuration, and the logit probability of supporting the mandate is obtained. The mean of these
        probabilities across draws is reported as “predicted public support”.
      </p>

      <h3>4.3. Coefficient tables used in the tool</h3>
      <p>
        The table below reports the mean coefficients used in eMANDEVAL-Future (corresponding to the mixed logit estimates
        imported into the tool).
      </p>

      <table>
        <thead>
          <tr>
            <th>Country / frame</th>
            <th>ASC Policy A</th>
            <th>ASC Opt-out</th>
            <th>Scope all</th>
            <th>Exemptions med+rel</th>
            <th>Exemptions med+rel+personal</th>
            <th>Coverage 70%</th>
            <th>Coverage 90%</th>
            <th>Lives saved (per 100k)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>Australia, mild</td>
            <td>0.464</td>
            <td>−0.572</td>
            <td>−0.319</td>
            <td>−0.157</td>
            <td>−0.267</td>
            <td>0.171</td>
            <td>0.158</td>
            <td>0.072</td>
          </tr>
          <tr>
            <td>Australia, severe</td>
            <td>0.535</td>
            <td>−0.694</td>
            <td>0.190</td>
            <td>−0.181</td>
            <td>−0.305</td>
            <td>0.371</td>
            <td>0.398</td>
            <td>0.079</td>
          </tr>
          <tr>
            <td>Italy, mild</td>
            <td>0.625</td>
            <td>−0.238</td>
            <td>−0.276</td>
            <td>−0.176</td>
            <td>−0.289</td>
            <td>0.185</td>
            <td>0.148</td>
            <td>0.039</td>
          </tr>
          <tr>
            <td>Italy, severe</td>
            <td>0.799</td>
            <td>−0.463</td>
            <td>0.174</td>
            <td>−0.178</td>
            <td>−0.207</td>
            <td>0.305</td>
            <td>0.515</td>
            <td>0.045</td>
          </tr>
          <tr>
            <td>France, mild</td>
            <td>0.899</td>
            <td>0.307</td>
            <td>−0.160</td>
            <td>−0.121</td>
            <td>−0.124</td>
            <td>0.232</td>
            <td>0.264</td>
            <td>0.049</td>
          </tr>
          <tr>
            <td>France, severe</td>
            <td>0.884</td>
            <td>0.083</td>
            <td>−0.019</td>
            <td>−0.192</td>
            <td>−0.247</td>
            <td>0.267</td>
            <td>0.398</td>
            <td>0.052</td>
          </tr>
        </tbody>
      </table>

      <p class="small">
        The corresponding standard deviations are also used to generate random draws and follow the mixed logit estimates
        in the main analysis. In the web tool, coefficient draws are implemented via independent standard normal draws
        scaled by these standard deviations and shifted by the means.
      </p>
    </section>

    <section class="card">
      <span class="pill">Costs &amp; benefits</span>
      <h2>5. Cost taxonomy and benefit metrics</h2>

      <h3>5.1. Cost categories</h3>
      <p>
        The costing framework in eMANDEVAL-Future mirrors standard components used in regulatory impact analyses for
        vaccine mandates and similar public health measures. It includes:
      </p>
      <ul>
        <li>Digital systems &amp; infrastructure (IT platforms, certificates, registries, integration).</li>
        <li>Communications &amp; public information (campaigns, materials, stakeholder engagement).</li>
        <li>Enforcement &amp; compliance (inspection, enforcement staff, penalties administration).</li>
        <li>Adverse-event monitoring &amp; compensation (pharmacovigilance and compensation schemes).</li>
        <li>Administration &amp; programme management (design, legal, coordination, oversight).</li>
        <li>Other mandate-specific costs (residual category for context-specific items).</li>
      </ul>
      <p>
        Version 2.0 includes stylised, per-million-population default costs by country and outbreak frame. These are
        scaled by the chosen population and analysis horizon, and can be loaded with a single click, then edited. They are
        placeholders to help users start; they must be replaced or calibrated against country-specific data, financial
        reports or regulatory impact assessments before formal use.
      </p>

      <h3>5.2. Benefit metrics and value per life saved / equivalent</h3>
      <p>
        The tool translates expected lives saved into monetary benefit using a single scalar “benefit metric”. Users can
        choose from several interpretations:
      </p>
      <ul>
        <li>
          <strong>Value of a statistical life (VSL):</strong> monetary value per life saved, aligned with national
          regulatory guidance where possible.
        </li>
        <li>
          <strong>Value of a statistical life-year (VSLY):</strong> value per life-year gained, which can be useful in
          age-structured or life-expectancy-adjusted analyses.
        </li>
        <li>
          <strong>Value per QALY gained:</strong> approximate willingness-to-pay per quality-adjusted life-year, aligned
          with health technology assessment thresholds.
        </li>
        <li>
          <strong>Health system cost savings per life saved:</strong> approximate lifetime healthcare costs avoided per
          prevented COVID-19 death.
        </li>
      </ul>
      <p>
        In all cases, the current implementation assumes a proportional mapping:
      </p>
      <p class="inline-math">
        Lives saved in population = (lives saved per 100,000) × (population / 100,000)
      </p>
      <p class="inline-math">
        Monetary benefit = (lives saved in population) × (benefit metric value)
      </p>
      <p class="highlight">
        Users should align the selected metric and the value entered with relevant national or institutional guidance and
        document the chosen value and its source when using eMANDEVAL-Future in formal policy analysis.
      </p>
    </section>

    <section class="card">
      <span class="pill secondary">Lives-saved equivalents</span>
      <h2>6. Lives-saved equivalents (MRS)</h2>
      <p>
        To aid interpretation of preferences for mandate design features, the tool reports “lives-saved equivalents”:
        changes in expected lives saved per 100,000 people that correspond to a given change in a mandate attribute.
      </p>
      <p>
        For a given attribute with coefficient β<sub>x</sub> and lives-saved coefficient β<sub>LS</sub>, the marginal rate
        of substitution (MRS) is:
      </p>
      <p class="inline-math">
        MRS<sub>x,LS</sub> = − β<sub>x</sub> / β<sub>LS</sub> (in “lives saved per 100,000 people” units).
      </p>
      <p>
        eMANDEVAL-Future uses the mean coefficients by country and frame to compute MRS for:
      </p>
      <ul>
        <li>Scope shift (high-risk only → all occupations &amp; public spaces).</li>
        <li>Exemption changes (for example medical only → medical + religious; medical only → medical + religious + personal).</li>
        <li>Coverage threshold changes (for example 50% → 70% or 90% vaccinated).</li>
      </ul>
      <p>
        The tool reports a short narrative alongside each MRS. Positive values indicate changes that make the mandate less
        preferred (equivalent to “losing” lives saved), while negative values indicate changes that make it more preferred
        (equivalent to “gaining” lives saved), from the perspective of average respondents in that country and frame.
      </p>
      <div class="subtle-box">
        <strong>Example:</strong> if raising the coverage threshold from 50% to 90% has MRS = 8, the change is viewed as
        about as demanding in acceptability terms as losing 8 expected lives saved per 100,000 people. This helps to
        communicate trade-offs in a common “lives-saved” scale.
      </div>
    </section>

    <section class="card">
      <span class="pill">Scenario comparison</span>
      <h2>7. Scenario storage, comparison dashboard and exports</h2>

      <h3>7.1. Saved scenarios</h3>
      <p>
        When a configuration and, optionally, costs have been applied, the user can save a scenario. Each saved scenario
        records:
      </p>
      <ul>
        <li>Settings (population, horizon, benefit metric and its value, currency label).</li>
        <li>Mandate configuration (country, outbreak frame, scope, exemptions, coverage, lives saved per 100,000).</li>
        <li>Cost inputs (by category and total).</li>
        <li>Derived metrics (lives saved, monetary benefit, net benefit, BCR, predicted support).</li>
      </ul>
      <p>
        Scenarios are stored in browser-local storage (under the key dedicated to eMANDEVAL-Future) and can be cleared at
        any time.
      </p>

      <h3>7.2. Comparison dashboard and pinned scenarios</h3>
      <p>
        The scenario comparison dashboard provides a compact visual summary of up to three “pinned” scenarios. For each
        pinned scenario, the dashboard shows:
      </p>
      <ul>
        <li>A succinct label (country, frame and a short descriptor derived from the configuration).</li>
        <li>A small radar-style visual comparing four dimensions: predicted support, BCR, total lives saved, total cost.</li>
        <li>
          Two traffic-light stripes, one for support and one for BCR, based on the thresholds used in the status chips
          (for example red for low, amber for medium, green for high).
        </li>
      </ul>
      <p>
        For pinned pairs, the tool also displays short textual deltas such as “Scenario B gains +12 percentage points in
        support and +0.3 in BCR relative to Scenario A”, helping senior decision-makers quickly identify attractive
        options.
      </p>
      <div class="chip-row">
        <span class="chip good">Support ≥ 70% &amp; BCR ≥ 1 &rarr; broadly favourable</span>
        <span class="chip med">Intermediate region &rarr; trade-off</span>
        <span class="chip bad">Support &lt; 50% &amp; BCR &lt; 1 &rarr; weak</span>
      </div>

      <h3>7.3. Exports and briefings</h3>
      <p>
        Saved scenarios can be exported as:
      </p>
      <ul>
        <li>CSV files (Excel-readable), one row per scenario with all inputs and key outputs.</li>
        <li>
          A Word document containing structured scenario summaries (configuration, benefits, costs, BCR, support) and a
          short, generic interpretation paragraph for each scenario.
        </li>
      </ul>
      <p>
        The Briefings &amp; AI prompts tab also auto-generates:
      </p>
      <ul>
        <li>
          A concise briefing template that can be adapted into internal notes, briefing papers or annexes for regulatory
          impact statements.
        </li>
        <li>
          A detailed AI prompt describing all saved scenarios, allowing tools such as Copilot or ChatGPT to produce
          comparative analyses, ministerial talking points or tailored policy briefs.
        </li>
      </ul>
      <p class="small">
        The exported documents and AI prompts are intended as starting points. They do not replace formal regulatory
        analysis or legal advice.
      </p>
    </section>

    <section class="card">
      <span class="pill">Worked examples</span>
      <h2>8. Worked examples (illustrative)</h2>
      <p>
        This section illustrates how to follow a configuration through the tool. The numbers below are examples and should
        be replaced by country-specific inputs and up-to-date guidance when used in practice.
      </p>

      <h3>8.1. Italy, severe outbreak</h3>
      <ul>
        <li><strong>Settings:</strong> population = 5,000,000; benefit metric = VSL; value per life saved = EUR&nbsp;5,000,000; horizon = 1 year.</li>
        <li>
          <strong>Configuration:</strong> scope = all occupations &amp; public spaces; exemptions = medical + religious;
          coverage threshold = 70%; expected lives saved = 25 per 100,000 people; outbreak frame = severe.
        </li>
        <li>
          <strong>Costing (illustrative):</strong> digital systems = EUR&nbsp;8m; communications = EUR&nbsp;3m;
          enforcement = EUR&nbsp;10m; compensation = EUR&nbsp;4m; administration = EUR&nbsp;2m; other = EUR&nbsp;3m.
        </li>
      </ul>
      <p>
        The tool converts the lives-saved input into total lives saved in the 5,000,000 population, applies the VSL to
        obtain the monetary benefit of lives saved, sums implementation costs, and computes the net benefit and BCR. The
        mixed logit model provides predicted support under the “Italy, severe” frame. Status chips and charts flag whether
        support and BCR appear high, medium or low.
      </p>

      <h3>8.2. Australia, mild outbreak</h3>
      <p>
        An analogous example can be set up for Australia under the mild frame, for example with a population of
        25,000,000 and a value per life saved consistent with Australian regulatory guidance. Changing only the outbreak
        frame (mild vs severe) while keeping the mandate structure fixed shows how the mixed logit coefficients shift
        predicted support across frames.
      </p>

      <h3>8.3. France, cross-country comparison</h3>
      <p>
        A further example can be built for France in the mild frame using the same mandate configuration as in the Italian
        example. Saving all three country scenarios allows the pinned comparison dashboard to highlight cross-country
        differences in support and BCR for “similar” mandates, conditional on any country-specific costing choices.
      </p>
    </section>

    <section class="card">
      <span class="pill">Governance</span>
      <h2>9. Versioning, quality control and limitations</h2>
      <p>
        eMANDEVAL-Future is structured to make updates transparent and auditable. The footer in the main application shows
        the version number and build date. This appendix includes a short changelog.
      </p>

      <h3>9.1. Internal quality checks</h3>
      <p>
        Before major releases, a small grid of test scenarios is defined and evaluated using both eMANDEVAL-Future and the
        original estimation environment (for example MATLAB or R). Predicted support, lives saved, benefit–cost metrics
        and lives-saved equivalents are cross-checked to ensure the web implementation reproduces the reference
        calculations up to expected rounding differences.
      </p>

      <h3>9.2. Limitations and responsibilities</h3>
      <p>
        The tool:
      </p>
      <ul>
        <li>
          Relies on stated-preference data from a DCE, which may not fully capture future behaviour, political dynamics or
          media environments.
        </li>
        <li>
          Uses simplified epidemiological inputs (lives saved per 100,000) that must be supplied externally, for example
          from transmission models or empirical studies.
        </li>
        <li>
          Applies stylised cost categories and, optionally, default cost levels that require calibration and validation
          before use in formal regulatory impact assessments.
        </li>
      </ul>
      <p class="note">
        Responsibility for the choice of inputs (benefit metric, cost values, epidemiological assumptions) and for the
        interpretation of outputs rests with the analyst or institution using the tool. The application is intended to
        support structured discussion of trade-offs, not to prescribe a particular policy.
      </p>

      <h3>9.3. Changelog</h3>
      <ul class="changelog">
        <li>
          <span class="tag">v2.0.0</span>
          Introduced a question-first workflow, multi-metric benefit valuation, country- and frame-specific default cost
          suggestions, pinned scenario comparison dashboard (radar view and traffic-light stripes), enhanced exports
          (Word briefing generator) and presentation mode. Core mixed logit coefficients and calculation logic unchanged
          from v1.0.0.
        </li>
        <li>
          <span class="tag">v1.0.0</span>
          First stable release (MANDEVAL). Integrated mixed logit preference estimates with a fixed set of 1,000 normal
          draws. Implemented settings, configuration, costing, results, scenario storage and briefing exports. Added
          lives-saved-equivalent (MRS) interpretations, status chips and AI-assisted briefing prompts.
        </li>
      </ul>
    </section>
  </div>
</body>
</html>
